Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis
References
- Metra M, Carubelli V, Ravera A, Stewart Coats AJ. Heart failure 2016: still more questions than answers. International Journal of Cardiology. 2016; 227: 766–777. DOI: 10.1016/j.ijcard.2016.10.060
- Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. Journal of the American College of Cardiology. 2014; 64(21): 2281–2293. DOI: 10.1016/j.jacc.2014.08.036
- Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. The American Journal of Cardiology. 1974; 34(1): 29–34. DOI: 10.1016/0002-9149(74)90089-7
- Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine. 2015; 373(22): 2117–2128. DOI: 10.1056/NEJMoa1504720
- Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. The New England Journal of Medicine. 2017; 377(7): 644–657. DOI: 10.1056/NEJMoa1611925
- Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine. 2019; 380(4): 347–357. DOI: 10.1056/NEJMoa1812389
- Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. The New England Journal of Medicine. 2019; 380(24): 2295–2306. DOI: 10.1056/NEJMoa1811744
- Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England Journal of Medicine. 2022; 387(12): 1089–1098. DOI: 10.1056/NEJMoa2206286
- Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England Journal of Medicine. 2021; 385(16): 1451–1461. DOI: 10.1056/NEJMoa2107038
- McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine. 2019; 381(21): 1995–2008. DOI: 10.1056/NEJMoa1911303
- Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. The New England Journal of Medicine. 2020; 383(15): 1413–1424. DOI: 10.1056/NEJMoa2022190
- Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, et al. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation. 2019; 140(18): 1463–1476. DOI: 10.1161/CIRCULATIONAHA.119.042929
- Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. The New England Journal of Medicine. 2021; 384(2): 117–128. DOI: 10.1056/NEJMoa2030183
- Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure. Journal of Cardiac Failure. 2022; 28(5): e1–e167. DOI: 10.1016/j.cardfail.2022.02.009
- Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022; 400(10354): 757–767. DOI: 10.1016/S0140-6736(22)01429-5
- Giugliano D, Longo M, Scappaticcio L, Bellastella G, Maiorino MI, Esposito K. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol. 2021; 20(1): 236. DOI: 10.1186/s12933-021-01430-3
- Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020; 396(10254): 819–829. DOI: 10.1016/S0140-6736(20)31824-9
- Xiang B, Zhang R, Wu X, Zhou X. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis. JAMA Netw Open. 2022; 5(9):
e2231963 . DOI: 10.1001/jamanetworkopen.2022.31963 - Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021; 372: n71. DOI: 10.1136/bmj.n71
- Higgins JPT, Altman DG.
Assessing risk of bias in included studies . In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Wiley, 2008. 187–241. DOI: 10.1002/9780470712184.ch8 - Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021; 27(11): 1954–1960. DOI: 10.1038/s41591-021-01536-x
- Palau P, Amiguet M, Domínguez E, Sastre C, Mollar A, Seller J, et al. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO(2)): a randomized clinical trial. Eur J Heart Fail. 2022; 24(10): 1816–1826. DOI: 10.1002/ejhf.2560
- Singh JSS, Mordi IR, Vickneson K, Fathi A, Donnan PT, Mohan M, et al. Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. Diabetes Care. 2020; 43(6): 1356–1359. DOI: 10.2337/dc19-2187
- Ibrahim A, Ghaleb R, Mansour H, Hanafy A, Mahmoud NM, Abdelfatah Elsharef M, et al. Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients With Decompensated Heart Failure and Reduced Ejection Fraction. Front Cardiovasc Med. 2020; 7: 602251. DOI: 10.3389/fcvm.2020.602251
- McMurray JJV, Wheeler DC, Stefánsson BV, Jongs N, Postmus D, Correa-Rotter R, et al. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. JACC Heart Fail. 2021; 9(11): 807–820. DOI: 10.1016/j.jchf.2021.06.017
- Pabel S, Hamdani N, Luedde M, Sossalla S. SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled? Curr Heart Fail Rep. 2021; 18(5): 315–328. DOI: 10.1007/s11897-021-00529-8
- Cai RP, Xu YL, Su Q. Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis. Cardiol Res Pract. 2021; 2021: 6657380. DOI: 10.1155/2021/6657380
- Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017; 104: 298–310. DOI: 10.1016/j.freeradbiomed.2017.01.035
- Zhai M, Du X, Liu C, Xu H. The Effects of Dapagliflozin in Patients With Heart Failure Complicated With Type 2 Diabetes: A Meta-Analysis of Placebo-Controlled Randomized Trials. Front Clin Diabetes Healthc. 2021; 2: 703937. DOI: 10.3389/fcdhc.2021.703937
- Anderson SL. Dapagliflozin efficacy and safety: a perspective review. Ther Adv Drug Saf. 2014; 5(6): 242–54. DOI: 10.1177/2042098614551938
- Anitha AP, Balasubramanian S, Ramalingam AG, Samuel Kennady SR, Ganamurali N, Dhanasekaran D, et al. An exploration of the experience of dapagliflozin in clinical practice. Future Sci OA. 2022; 8(8): Fso816. DOI: 10.2144/fsoa-2022-0038
- Blair HA. Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction. Am J Cardiovasc Drugs. 2021; 21(6): 701–710. DOI: 10.1007/s40256-021-00503-8
- Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15): 1436–1446. DOI: 10.1056/NEJMoa2024816
DOI: https://doi.org/10.5334/gh.1258 | Journal eISSN: 2211-8179
Language: English
Submitted on: May 15, 2023
Accepted on: Jul 24, 2023
Published on: Aug 22, 2023
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2023 Ahmed E. Ali, Muhammad Sabry Mazroua, Mariam ElSaban, Nadia Najam, Aditi S. Kothari, Taha Mansoor, Tanya Amal, Joanna Lee, Rahul Kashyap, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.